Sponsor Deadline
Posted: 4/18/2022

Biosimilars in Hematologic Malignancies & Supportive Care

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

The professional education goal of this RFP is to support the prudent (safe and effective) use of biologic drugs in patients with hematologic malignancies or for use in supportive care by: • Increasing clinicians’ understanding of complex biosimilar concepts including, the analytical foundation, clinical data analysis for biosimilars and global differences in the regulatory framework governing the approval of biosimilar drugs. • Implementing practical approaches to the incorporation of biosimilars into hematology-oncology practice in all label indications, including protocols, guidelines and pathways. Including, improving the ability of healthcare professionals to discuss biosimilar options with their patients as part of shared-decision-making • Discussing emerging RWE from biosimilars in hematologic malignancies and RWE data gaps preventing full utilization the health care utilization • Discussing available data regarding Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia • Discuss the use of Granulocyte Colony-Stimulating Factors in the SARS-2 (covid19) era and the role of biosimilars to reduce hospital cost burden • Overcoming global roadblocks to help realize the potential for costsavings of biosimilars in hematologic malignancies and in supportive care and the overall benefit to reducing healthcare costs in society.

Grant Application due date: November 2, 2020

Eligibility Requirements

Geographic Scope: Global

• The following may apply medical practitioners, healthcare institutions (both academic and community practices); professional associations and medical societies; and other entities with a mission related to healthcare professional education and/or healthcare improvement. • If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. all institutions must have a relevant role and the requesting organization must have a key role in the project. • For projects offering continuing education credit, the requesting organization must be accredited.

Amount Description

Individual projects requesting up to $200,000 will be considered. The estimated total available budget related to this RFP is $600,000.

Smaller educational proposals are encouraged. Organizations that would like to develop activities for a more limited regional or local group of healthcare providers should also apply. Typically grant amounts for local or regional activities should not exceed around $50,000 USD.

Funding Type